Evidence map›Paper›PMID 40694243›Full record

ArticleEJNMMI radiopharmacy and chemistry2025

Development and evaluation of a

Wei Xu, Junjie Yan, Xinlin Zhong, Donghui Pan, Xinyu Wang, Yuping Xu, Lizhen Wang, Chongyang Chen, Min Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wei XuSchool of Life Sciences and Health Engineering, Jiangnan University, Jiangsu, 214122, China.
Junjie YanNHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Jiangsu, 214063, China. yanjunjie@jsinm.org.
Xinlin ZhongSchool of Life Sciences and Health Engineering, Jiangnan University, Jiangsu, 214122, China.
Donghui PanNHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Jiangsu, 214063, China.
Xinyu WangNHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Jiangsu, 214063, China.
Yuping XuNHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Jiangsu, 214063, China.
Lizhen WangNHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Jiangsu, 214063, China.
Chongyang ChenNHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Jiangsu, 214063, China.
Min YangSchool of Life Sciences and Health Engineering, Jiangnan University, Jiangsu, 214122, China. yangmin@jsinm.org.ORCID http://orcid.org/0000-0001-6976-8526

Funding

National Natural Science Foundation of China 32371434
6 · The paper itself

Abstract

backgroundPoly(ADP-ribose) polymerase (PARP) is an important therapeutic target in cancer treatment, and dynamic assessment of its expression level is essential for achieving precision therapy. Although

results[

conclusionThese findings suggest that [

Indexed as

99mTcCancer diagnosisOlaparibPARPSPECT imaging

Identifiers

PMID40694243
PMCPMC12283529

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.